Novelties in the field of antimicrobial compounds for the treatment of lower respiratory tract infections

Pulmonary Pharmacology and Therapeutics

Volumn 16, Issue 3, 2003, Pages 131-145

  Cazzola, Mario ^a   Sanduzzi, Alessandro ^b   Matera, Maria Gabriella ^c  

^a CARDARELLI HOSPITAL   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cationic peptides lipopeptides; Oxazolidinones; Peptide deformylase inhibitors; Pleuromutilins

Indexed keywords

ANTIINFECTIVE AGENT; EPEREZOLID; LINEZOLID; LIPOPEPTIDE; OXAZOLIDINONE DERIVATIVE; PEPTIDE DEFORMYLASE INHIBITOR; PLEUROMUTILIN; PNU 107922; PNU 140457; PNU 172576; PNU 176798; PNU 288034; POLYPEPTIDE ANTIBIOTIC AGENT; POSIZOLID; UNCLASSIFIED DRUG; VRC 3125; VRC 3783;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESEARCH; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIVER DISEASE; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MYCOSIS; NAUSEA; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL; SENSORY DYSFUNCTION; THROMBOCYTOPENIA; VAGINA CANDIDIASIS; VOMITING;

EID: 0038670774     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1094-5539(03)00050-6     Document Type: Article

References (109)

1. Cazzola M., Blasi F., Centanni S., et al. Advances in the research and development of chemotherapeutic agents for respiratory tract bacterial infections. Pulm Pharmacol Ther. 14:2001;367-381.
2. Slee A.M., Wuonola M.A., McRipley R.J., et al. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob Agents Chemother. 31:1987;1791-1797.
3. Shinabarger D.L., Marotti K.R., Murray R.W., et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother. 41:1997;2132-2136.
4. Swaney S.M., Aoki H., Ganoza M.C., et al. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother. 42:1998;3251-3255.
5. Dresser L.D., Rybak M.J. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy. 18:1998;456-462.
6. Pawsey SD, Daley-Yates PT, Wajszczuk CP, et al. U-100766 safety, toleration and pharmacokinetics after oral and intravenous administration. Program and abstracts of the First European Congress of Chemotherapy; 1996. p. F151.
7. Cercenado E., García-Garrote F., Bouza E. In vitro activity of linezolid against multiply resistant Gram-positive clinical isolates. J Antimicrob Chemother. 47:2001;77-81.
8. Fines M., Leclercq R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother. 45:2000;797-802.
9. Mutnick A.H., Biedenbach D.J., Turnidge J.D., et al. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis. 43:2002;65-73.
10. Tsiodras S., Gott H.S., Sakoulas G., et al. Linezo-lid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 358:2001;207-208.
11. Prystowsky J., Siddiqui F., Chosay J., et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother. 45:2001;2154-2156.
12. Munckhof W.J., Giles C., Turnidge J.D. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria. J Antimicrob Chemother. 47:2001;879-883.
13. Gee T., Ellis R., Marshall G., et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother. 45:2001;1843-1846.
14. Hyatt J.M., McKinnon P.S., Zimmer G.S., et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers of outcome. Focus on antibacterial agents. Clin Pharmacokinet. 28:1995;143-160.
15. Ford C., Hamel J., Stapert D., et al. Oxazolidinones: a new class of antimicrobials. Infect Med. 16:1999;435-445.
16. Conte J.E. Jr, Golden J.A., Kipps J., et al. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother. 46:2002;1475-1480.
17. Gentry-Nielsen M.J., Olsen K.M., Preheim L.C. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother. 46:2002;1345-1351.
18. San Pedro G.S., Cammarata S.K., Oliphant T.H., et al. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis. 34:2002;720-728.
19. Kaplan S.L., Patterson L., Edwards K.M., et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Linezolid Pediatric Pneumonia Study Group. Pediatr Infect Dis J. 20:2001;488-494.
20. Rubinstein E., Cammarata S., Oliphant T., et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 32:2001;402-412.
21. Stevens D.L., Herr D., Lampiris H., et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 34:2002;1481-1490.
22. Linden P. Use of linezolid for Gram-positive infections. Infect Med. 19:2002;25-32.
23. Green S.L., Maddox J.C., Huttenback E.D. Linezolid and reversible myelosuppression. JAMA. 285:2001;1291.
24. Attassi K., Hershberger E., Alam R., et al. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis. 34:2002;695-698.
25. Li Z., Willke R.J., Pinto L.A., et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy. 21:2001;263-274.
26. Li J.Z., Willke R.J., Rittenhouse B.E., et al. Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. Pharmacotherapy. 22:2002;45S-54S.
27. Genin M.J., Hutchinson D.K., Allwine D.A., et al. Nitrogen-carbon-linked (azolylphenyl)oxazolidinones with potent antibacterial activity against the fastidious Gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis. J Med Chem. 41:1998;5144-5147.
28. Barbachyn M.R., Brickner S.J., Gadwood R.C., et al. Design, synthesis, and evaluation of novel oxazolidinone antibacterial agents active against multidrug-resistant bacteria. Adv Exp Med Biol. 456:1998;219-238.
29. Genin M.J., Allwine D.A., Anderson D.J., et al. Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious Gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis. J Med Chem. 43:2000;953-970.
30. Brown SD, Barry AL, Fuchs PC, et al. PNU-288034: in vitro potency compared to linezolid, spectrum of antimicrobial activity, and confirmation of disk mass. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California; September 27-30, 2002. Abst F-1337.
31. Baum S.E., Crawford S.A., McElmeel M.L., et al. Antimicrob Agents Chemother. 46:2002;3094-3095.
32. Fluit A.C., Schmitz F.J., Verhoef J., et al. In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci. J Antimicrob Chemother. 50:2002;271-276.
33. Kubo A, Press B, Luehr GW, et al. In vitro activity of novel oxazolidinones against Chlamydia. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California; September 27-30, 2002. Abst F-1322.
34. Weidner-Wells M.A., Boggs C.M., Foleno B.D., et al. Novel piperidinyloxy oxazolidinone antibacterial agents. Diversification of the N-substituent. Bioorg Med Chem. 10:2002;2345-2351.
35. Choi S, Lee T, Im W, et al. In vitro antibacterial activity of DA-7867, a new oxazolidinone. Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California; September 27-30, 2002. Abst F-1313.
36. Ganz T. Defensins and host defense. Science. 286:1999;420-421.
37. Goldman M.J., Anderson G.M., Stolzenberg E.D., et al. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell. 88:1997;553-560.
38. McCray P. Jr, Bentley L. Human airway epithelia express a β-defensin. Am J Respir Cell Mol Biol. 16:1997;343-349.
39. Harder J., Bartels J., Christophers E., et al. A peptide antibiotic from human skin. Nature. 387:1997;861.
40. Bals R., Wang X., Zasloff M., et al. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA. 95:1998;9541-9546.
41. Yang D., Chen Q., Schmidt A.P., et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T-cells. J Exp Med. 192:2000;1069-1074.
42. Yang D., Chertov O., Bykovskaia S., et al. β-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science. 286:1999;525-528.
43. Le Y., Li B., Gong W., et al. Novel pathophysiological role of classical chemotactic peptide receptors and their communications with chemokine receptors. Immunol Rev. 177:2000;185-194.
44. Johansen C., Verheul A., Gram L., et al. Protamine-induced permeabilization of cell envelopes of Gram-positive and Gram-negative bacteria. Appl Environ Microbiol. 63:1997;1155-1159.
45. Hancock R.E.W., Nair P. Cationic antimicrobial peptide antibiotics. Curr Opin Anti-infect Invest Drugs. 2:2000;140-144.
46. Stark M., Liu L.P., Deber C.M. Cationic hydrophobic peptides with antimicrobial activity. Antimicrob Agents Chemother. 46:2002;3585-3590.
47. Oren Z., Shai Y. Mode of action of linear amphipathic α-helical antimicrobial peptides. Biopolymers. 47:1998;451-463.
48. Scott M.G., Hancock R.E. Cationic antimicrobial peptides and their multifunctional role in the immune system. Crit Rev Immunol. 20:2000;407-431.
49. Hancock R.E., Chapple D.S. Peptide antibiotics. Antimicrob Agents Chemother. 43:1999;1317-1323.
50. Andra J., Leippe M. Pore-forming peptide of Entamoeba histolytica. Significance of positively charged amino acid residues for its mode of action. FEBS Lett. 354:1994;97-102.
51. Cabiaux V., Agerberth B., Johansson J., et al. Secondary structure and membrane interaction of PR-39, a Pro rich antibacterial peptide. Eur J Biochem. 224:1994;1019-1027.
52. Andreu D., Rivas L. Animal antimicrobial peptides: an overview. Biopolymers. 47:1998;415-433.
53. Ganz T., Lehrer R.I. Antibiotic peptides from higher eukaryotes: biology and applications. Mol Med Today. 5:1999;292-297.
54. Cirioni O., Giacometti A., Ghiselli R., et al. Single-dose intraperitoneal magainins improve survival in a Gram-negative-pathogen septic shock rat model. Antimicrob Agents Chemother. 46:2002;101-104.
55. Ge Y., MacDonald D.L., Holroyd K.J., et al. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother. 43:1999;782-788.
56. Navon-Venezia S., Feder R., Gaidukov L., et al. Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob Agents Chemother. 46:2002;689-694.
57. Travis S.M., Anderson N., Forsyth W.R., et al. Bactericidal activity of mammalian cathelicidin peptides. Infect Immun. 68:2000;2748-2755.
58. Skerlavaj B., Benincasa M., Risso A., et al. SMAP29: a potent antibacterial and antifungal peptide from sheep leukocytes. FEBS Lett. 463:1999;56-58.
59. Hancock R.E.W. Peptide antibiotics. Lancet. 349:1997;418-422.
60. Saiman L., Tabibi S., Starner T.D., et al. Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother. 45:2001;2838-2844.
61. Andersson M., Gunne H., Agerberth B., et al. NK-lysin, a novel effector peptide of cytotoxic T and NK cells: structure and cDNA cloning of the porcine form, induction by interleukin 2, antibacterial and antitumour activity. EMBO J. 14:1995;1615-1625.
62. Krensky A.M., Okada S., Clayberger C., et al. Granulysin: a novel antimicrobial. Exp Opin Investigat Drugs. 10:2001;321-329.
63. Wang Z., Choice E., Kaspar A., et al. Bactericidal and tumoricidal activities of synthetic peptides derived from granulysin. J Immunol. 165:2000;1486-1490.
64. Hamamoto K., Kida Y., Zhang Y., et al. Antimicrobial activity and stability to proteolysis of small linear cationic peptides with D-amino acid substitutions. Microbiol Immunol. 46:2002;741-749.
65. MacKay B.J., Denepitiya L., Iacono V.J., et al. Growth-inhibitory and bactericidal effects of human parotid salivary histidine-rich polypeptides on Streptococcus mutans. Infect Immun. 44:1984;695-701.
66. Sajjan U.S., Tran L.T., Sole N., et al. P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrob Agents Chemother. 45:2001;3437-3444.
67. Paquette D.W., Waters G.S., Stefanidou V.L., et al. Inhibition of experimental gingivitis in beagle dogs with topical salivary histatins. J Clin Periodontol. 24:1997;216-222.
68. Mickels N., McManus C., Massaro J., et al. Clinical and microbial evaluation of a histatin containing mouthrinse in humans with experimental gingivitis. J Clin Periodontol. 28:2001;404-410.
69. Kokryakov V.N., Harwig S.S.L., Panyutich E.A., et al. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Lett. 327:1993;231-236.
70. Harwig S.S.L., Waring A.J., Yang H.J., et al. Intramolecular disulfide bonds enhance the antimicrobial and lytic activities of protegrins at physiological sodium chloride concentrations. Eur J Biochem. 240:1996;352-357.
71. Steinberg D.A., Hurst M.A., Fujii C.A., et al. Protegrin-1: a broad-spectrum, rapidly microbicidal peptide with in vivo activity. Antimicrob Agents Chemother. 41:1997;1738-1742.
72. Hancock R.E.W., Lehrer R.I. Cationic peptides a new source of antibiotics. Trends Biotech. 16:1998;82-88.
73. Albrecht M.T., Wang W., Shamova O., et al. Binding of protegrin-1 to Pseudomonas aeruginosa and Burkholderia cepacia. Respir Res. 14:(3(1)):2002;18.
74. Mosca D.A., Hurst M.A., So W., et al. IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis. Antimicrob Agents Chemother. 44:2000;1803-1808.
75. Toney J.H. Iseganan (IntraBiotics pharmaceuticals). Curr Opin Investigat Drugs. 3:2002;225-228.
76. Levy O. A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein. Antimicrob Agents Chemother. 44:2000;2925-2931.
77. Gazzano-Santoro H., Parent J.B., Grinna L., et al. High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect Immun. 60:1992;4754-4761.
78. Mannion B.A., Kalatzis E.S., Weiss J., et al. Preferential binding of the neutrophil cytoplasmic granule-derived bactericidal/permeability increasing protein to target bacteria. Implications and use as a means of purification. J Immunol. 142:1989;2807-2812.
79. Giroir B.P., Quint P.A., Barton P., et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet. 350:1997;1439-1443.
80. von der Mohlen M.A., Kimmings A.N., Wedel N.I., et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis. 172:1995;144-151.
81. Urban C., Mariano N., Rahal J.J., et al. Polymyxin B-resistant Acinetobacter baumannii clinical isolate susceptible to recombinant BPI21 and Cecropin P1. Antimicrob Agents Chemother. 45:2001;994-995.
82. Mayo K.H., Haseman J., Ilyina E., et al. Designed β-sheet-forming peptide 33mers with potent human bactericidal/permeability increasing protein-like bactericidal and endotoxin neutralizing activities. Biochim Biophys Acta. 1425:1998;81-92.
83. Tally F.P., Zeckel M., Wasilewski M.M., et al. Daptomycin: a novel agent for Gram-positive infections. Exp Opin Invest Drugs. 8:1999;1223-1238.
84. Tally F.P., DeBruin M.F. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother. 46:2000;523-526.
85. Canepari P., Boaretti M., Del Mae Lleo M., et al. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother. 34:1990;1220-1226.
86. Alborn W.E. Jr, Allen N.E., Treston D.A. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother. 35:1991;2639-2642.
87. Rybak M.J., Hershberger E., Moldovan T., et al. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother. 44:2000;1062-1066.
88. Snydman D.R., Jacobus N.V., McDermott L.A., et al. Comparative in vitro activities of daptomycin and vancomycin against resistant Gram-positive pathogens. Antimicrob Agents Chemother. 44:2000;3447-3450.
89. Pankuch G.A., Jacobs M.R., Appelbaum P.C. Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials. J Antimicrob Chemother. 51:2003;443-446.
90. Wise R., Andrews J.M., Ashby J.P. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother. 48:2001;563-567.
91. Silverman J.A., Oliver N., Andrew T., et al. Resistance studies with daptomycin. Antimicrob Agents Chemother. 45:2001;1799-1802.
92. Akins R.L., Rybak M.J. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother. 44:2000;1925-1929.
93. Lee B.L., Sachdeva M., Chambers H.F. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 35:1991;2505-2508.
94. Wise R., Gee T., Andrews J.M., et al. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother. 46:2002;31-33.
95. Woodworth J.R., Nyhart E.H. Jr, Brier G.L., et al. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother. 36:1992;318-325.
96. Louie A., Kaw P., Liu W., et al. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother. 45:2001;845-851.
97. Dvorchik B, Sica D, Gehr T. Pharmacokinetics (PK) and safety of single-dose daptomycin in subjects with graded renal insufficiency and end-stage renal disease (ESRD). Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego; 2002. Abst A-1387.
98. Oleson F.B. Jr, Berman C.L., Kirkpatrick J.B., et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother. 44:2000;2948-2953.
99. Arbeit RD, Debruin MF. Daptomycin (DAP), a novel lipopeptide antibiotic, in the treatment of complicated skin and soft tissue infections (cSSTI): combined results of two phase III studies (99-01 and 98-01). Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago; 2001. Abst UL-19.
100. Chen D.Z., Patel D.V., Hackbarth C.J., et al. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry. 39:2000;1256-1262.
101. Broughton B.J., Chaplen P., Freeman W.A., et al. Studies concerning the antibiotic actinonin. Part VIII. Structure-activity relationships in the actinonin series. J Chem Soc Perkin Trans. 1:1975;857-860.
102. Clements J.M., Beckett R.P., Brown A., et al. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother. 45:2001;563-570.
103. Hackbarth C.J., Chen D.Z., Lewis J.G., et al. N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother. 46:2002;2752-2764.
104. Jones R.N., Rhomberg P.R. Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J Antimicrob Chemother. 51:2003;157-161.
105. Clements JM. Peptide deformylase inhibitors as novel antimicrobial agents. Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago; 2001. Abst 9.
106. Rittenhouse S, Moore T, Donald B, et al. In vitro activity of two novel pleuromutilin derivatives, SB-247386 and SB-268091. Program and Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco; 1999. Abst 1805.
107. Brooks G., Burgess W., Colthurst D., et al. Pleuromutilins. Part 1. The identification of novel mutilin 14-carbamates. Bioorg Med Chem. 9:2001;1221-1231.
108. Heilmann C., Jensen L., Jensen J.S., et al. Treatment of resistant mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic. J Infect. 43:2001;234-238.
109. Blasi F., Braga P., Cazzola M., et al. Therapies in development for community-acquired pneumonia. Exp Opin Investigat Drugs. 11:2002;545-552.